[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$alnys](/topic/$alnys) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Truist Securities reviews biotech performance in 3Q noting a strong sector rebound with XBI up 32%. Key companies like $ALNY and $BBIO are set for earnings beats. $ALNY's price target rises to $XXX. Positive sentiment is growing in biotech #Biotech @grok" [X Link](https://x.com/CryptoMilox/status/1979170201175236642) [@CryptoMilox](/creator/x/CryptoMilox) 2025-10-17T12:58Z 1080 followers, XXX engagements "$60B MC $alny's biz dev team needs to be summarily fired for not taking advantage of #CRISPR firesale prices not long ago. CRISPR $ntla will eat a lot of its market share in the not too distant future. What were they thinking" [X Link](https://x.com/RNAiAnalyst/status/1975988277321793649) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-08T18:14Z 20.6K followers, 4833 engagements "$NTLA I believe the ATTR-PN phase X data will be even better than the one reported today mainly because p3 does not include patients that had progressed on $ALNY's RNAi agents before. As you can see they did worse than knockdown-naive subjects" [X Link](https://x.com/RNAiAnalyst/status/1971291795968622899) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-09-25T19:12Z 20.5K followers, 4231 engagements "Im XX% certain that these analysts are counting Gen X as Amvuttra too because there is ZERO chance Amvuttra EVER makes $9.2B in a year. $ALNY $NTLA I can see their Gen X (Nucresiran) making that though. In X weeks Intellia will essentially show that doctors will morally be unable to prescribe Amvuttra (once Nex Z is available). Ex: Do you want to worsen by XX% in your first year or not And Alnylam got their data with the healthiest group of patients by far (Hurt them on curves but helped them on majority of other things)" [X Link](https://x.com/GeneInvesting/status/1969207429281038771) [@GeneInvesting](/creator/x/GeneInvesting) 2025-09-20T01:10Z 14.5K followers, 6907 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Truist Securities reviews biotech performance in 3Q noting a strong sector rebound with XBI up 32%. Key companies like $ALNY and $BBIO are set for earnings beats. $ALNY's price target rises to $XXX. Positive sentiment is growing in biotech #Biotech @grok"
X Link @CryptoMilox 2025-10-17T12:58Z 1080 followers, XXX engagements
"$60B MC $alny's biz dev team needs to be summarily fired for not taking advantage of #CRISPR firesale prices not long ago. CRISPR $ntla will eat a lot of its market share in the not too distant future. What were they thinking"
X Link @RNAiAnalyst 2025-10-08T18:14Z 20.6K followers, 4833 engagements
"$NTLA I believe the ATTR-PN phase X data will be even better than the one reported today mainly because p3 does not include patients that had progressed on $ALNY's RNAi agents before. As you can see they did worse than knockdown-naive subjects"
X Link @RNAiAnalyst 2025-09-25T19:12Z 20.5K followers, 4231 engagements
"Im XX% certain that these analysts are counting Gen X as Amvuttra too because there is ZERO chance Amvuttra EVER makes $9.2B in a year. $ALNY $NTLA I can see their Gen X (Nucresiran) making that though. In X weeks Intellia will essentially show that doctors will morally be unable to prescribe Amvuttra (once Nex Z is available). Ex: Do you want to worsen by XX% in your first year or not And Alnylam got their data with the healthiest group of patients by far (Hurt them on curves but helped them on majority of other things)"
X Link @GeneInvesting 2025-09-20T01:10Z 14.5K followers, 6907 engagements
/topic/$alnys/posts